A
NYSEAgilent Technologies Inc.
Price$153.22-1.60 (-1.03%)
01:30 PM07:30 PM
News · 26 weeks66-100%
2026-03-012026-08-23
Mix2790d
- Other13(48%)
- Analyst5(19%)
- Insider4(15%)
- SEC Filings3(11%)
- Earnings2(7%)
Latest news
25 items- PRAgilent Research Catalyst Award Presented to Eastern Institute of Technology, NingboEastern Institute of Technology professor recognized for advancing PFAS and emerging contaminant analysis Agilent Technologies Inc. (NYSE:A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on behalf of Professor Zongwei Cai. The award recognizes Professor Cai's innovative research focused on developing advanced analytical approaches for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, a growing area of importance for environmental and public health research. Professor Cai is a globally recognized leader in environmental and bioanalytical chemistry. His research focuses on advancin
- PRAgilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26Agilent Technologies Inc. (NYSE:A) will release financial results for the third quarter of fiscal year 2026 after the stock market closes on Wednesday, Aug. 26. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent’s Investor Relations website. A recording of the call will also be available on the website for 90 days. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full
- PRAgilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaApproval expands PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab) Agilent Technologies Inc. (NYSE:A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, enables pathologists to assess PD-L1 expression to identify patients with epithelial ovarian, fallopian tube
- PRAgilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal AdenocarcinomaTest enables identification of patients whose tumors express PD-L1 and who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® Agilent Technologies Inc. (NYSE:A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb’s PD‑1‑targeted immunotherapeutic agents. PD-L1 IHC 28-8 pharmDx is approved for exclusi
- ANALYSTJefferies resumed coverage on Agilent with a new price targetJefferies resumed coverage of Agilent with a rating of Hold and set a new price target of $135.00
- PRAgilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic AnalysisAgilent Technologies Inc. (NYSE:A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides, and conjugated therapeutics. Applications such as aggregate characterization, molecular weight confirmation and size distribution analysis remain essential for evaluating product quality, stability and performance, while drug-to-antibody
- PRAgilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSightSimplifying label-free imaging analysis for more confident real-time cell analysis Agilent Technologies Inc. (NYSE:A) today announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to gain imaging and impedance insights from the same cells in the same experiment with greater speed and confidence. This streamlined, integrated approach i
- INSIDERSenior Vice President Kirkwood Jonah Prevost covered exercise/tax liability with 30 shares, decreasing direct ownership by 0.21% to 14,108 units (SEC Form 4)4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- ANALYSTBernstein resumed coverage on Agilent with a new price targetBernstein resumed coverage of Agilent with a rating of Outperform and set a new price target of $155.00
- SECAgilent Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
- PRExcellere Partners and GHO Capital complete sale of Biocare Medical to Agilent TechnologiesDenver, CO and London, UK – 25 June 2026: Excellere Partners ("Excellere"), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, and GHO Capital Partners LLP ("GHO"), a specialist investor in global healthcare, today announced the completion of the sale of Biocare Medical ("Biocare"), a global leader in immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions, to Agilent Technologies, Inc. ((", Agilent", , NYSE:A). Under the stewardship of Excellere and GHO, the company delivered annual double-digit revenue and profitability growth, strengthened its core IHC business, expanded into molec
- PRAgilent Completes Acquisition of Biocare MedicalHighly complementary combination expands Agilent’s pathology portfolio and ability to serve customers across clinical and research settingsExpected to be accretive to Agilent’s top-line growth rate, margin profile and non-instrument revenue mix in the first yearAgilent Technologies Inc. (NYSE:A) today announced the successful completion of its previously announced acquisition of Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP. Following the close of the transaction, Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group."We are pleased to complete our acquisition of Biocare, which repr
- ANALYSTPiper Sandler initiated coverage on Agilent with a new price targetPiper Sandler initiated coverage of Agilent with a rating of Neutral and set a new price target of $150.00
- INSIDERNew insider Downs Timothy Charles claimed ownership of 8,872 shares (SEC Form 3)3 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- INSIDERPresident and CEO Mcdonnell Padraig covered exercise/tax liability with 418 shares, decreasing direct ownership by 0.63% to 65,842 units (SEC Form 4)4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- PRAgilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific InnovationAgilent Technologies Inc. (NYSE:A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company's products, operations, and customer workflows. "AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation value for our customers," said Padraig McDonnell, president and CEO of Agilent. "Through this collaboration with OpenAI and BCG, we are accelerating deployment of AI across our business while advancing more intelligent instruments, soft
- PRAgilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction AdenocarcinomaApproval expands PD-L1 testing onto an automated workflow to support treatment decisions with KEYTRUDA® (pembrolizumab)¹,² Agilent Technologies Inc. (NYSE:A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. This approval expands access to PD-L1 testing across
- INSIDERDirector Dolsten Mikael sold $216,672 worth of shares (1,600 units at $135.42), decreasing direct ownership by 22% to 5,548 units (SEC Form 4)4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- SECSEC Form 10-Q filed by Agilent Technologies Inc.10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
- SECSEC Form SD filed by Agilent Technologies Inc.SD - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
- ANALYSTAgilent upgraded by BofA Securities with a new price targetBofA Securities upgraded Agilent from Neutral to Buy and set a new price target of $145.00
- PRAgilent Introduces OpenLab Sync to Support Guided, Digital Execution in the LaboratoryAgilent Technologies Inc. (NYSE:A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent's OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As laboratories face increasing regulatory scrutiny, workforce turnover, and pressure to standardize operations across sites, many continue to rely on static, paper-based procedures that can introduce variability and risk. OpenLab Sync addr
- SECAgilent Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
- PRAgilent Reports Second-Quarter Fiscal Year 2026 Financial ResultsDelivers strong Q2 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS(4) guidance on continued operational momentum Second-quarter fiscal year 2026 Revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core(1) compared with the second quarter of 2025. GAAP operating margin of 21.7%; non-GAAP operating margin(2) of 26.4% expanded by 130 basis points year-over-year and 180 basis points sequentially. GAAP net income of $339 million; earnings per share (EPS) of $1.20, an increase of 60% from the second quarter of 2025. Non-GAAP net income(3) of $423 million; non-GAAP EPS(3) of $1.49, an incre
- ANALYSTRBC Capital Mkts initiated coverage on Agilent with a new price targetRBC Capital Mkts initiated coverage of Agilent with a rating of Outperform and set a new price target of $153.00
A FAQ
8 questionsWhat does Agilent Technologies Inc. do?
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems...Where does A stock trade?
Agilent Technologies Inc. (A) is listed on NYSE.What sector and industry is A in?
Agilent Technologies Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did Agilent Technologies Inc. go public?
Agilent Technologies Inc. (A) completed its IPO in 1999.Does A pay a dividend?
A's most recent ex-dividend date was 2026-06-30 with a cash dividend of $0.26 per share. No future ex-date is on file yet.What are analysts saying about A?
Agilent Technologies Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Hold on 2026-07-09.What companies are similar to A?
Notable peers in the same industry include TMO (Thermo Fisher Scientific Inc), WAT (Waters Corporation), PKI (PerkinElmer Inc.). Compare A side-by-side with any of them on Quantisnow.How can I track A on Quantisnow?
Quantisnow aggregates Agilent Technologies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow A to receive live email and push alerts on every new disclosure.